logo

Verastem, Inc. (VSTM)



Trade VSTM now with
  Date
  Headline
11/22/2021 7:41:07 AM Mirati, Verastem Partner To Evaluate Adagrasib In Combination With VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer
9/22/2021 7:08:06 AM Verastem Oncology Appoints Louis Denis As Chief Medical Officer
9/20/2021 7:11:30 AM Verastem Oncology,Amgen Partner To Evaluate VS-6766 In With LUMAKRASTM In Patients With KRAS G12C-Mutant NSCLC
9/19/2021 12:05:06 PM Verastem Oncology Presents Updated Phase 1/2 FRAME Data Of VS-6766 With Defactinib In Serous Ovarian Cancer At ESMO
7/6/2021 7:05:57 AM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/24/2021 7:11:15 AM Verastem Oncology Appoints Paul Bunn And Lesley Solomon To Board
5/24/2021 7:09:16 AM Verastem Gets Breakthrough Therapy Designation For VS-6766 With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer
1/6/2021 9:15:20 AM Verastem Appoints Frank Neumann As Chief Medical Officer
11/30/2020 7:11:25 AM Verastem Oncology Initiates Phase 2 Registration-Directed Trial Of VS-6766
10/28/2020 9:06:18 PM Verastem Oncology New Data Supports Potential Of VS-6766 As Treatment For RAS Mutant Tumors
10/6/2020 7:23:43 AM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/30/2020 8:58:09 AM Verastem Completes Sale Of COPIKTRA Or Duvelisib To Secura Bio
9/16/2020 7:07:13 AM Verastem Oncology To Present Updated Phase 1/2 FRAME Study Data At Annual RAS-Targeted Drug Development Summit